Malassezia

Skin Commensal Role#

Colonizes lipid-rich skin sites (scalp, face, chest, back) where it metabolizes host sebum triglycerides via secreted lipases, releasing unsaturated fatty acids (oleic acid) that can trigger Metal-Driven Inflammation in susceptible individuals.

M. restricta is the primary causative agent of dandruff and seborrheic dermatitis through lipase-mediated oleic acid release and subsequent inflammation. M. furfur causes pityriasis versicolor (skin depigmentation) and can cause systemic fungemia in neonates receiving lipid parenteral nutrition.

The genus is uniquely lipid-dependent—it lacks the genes for de novo fatty acid synthesis and must acquire lipids from its environment.

Gut Mycobiome Presence#

Despite being considered a skin organism, Malassezia is consistently detected in gut mycobiome surveys, likely arriving via ingestion and possibly establishing transient or semi-permanent colonization.

In the gut, Malassezia interacts with bacterial communities: negatively correlated with Bifidobacterium, Roseburia, and Ruminococcus in IBD patients.^{[1]Unveiling the overlooked fungi: the vital of gut fungi in inflammatory bowel disease and colorectal cancerYilin Huang, Yang Wang, Xiaotian Huang et al. · 2024Open reference 1 ↓}

Positively correlated with Candida albicans and Aspergillus in ASD gut mycobiome.^{[2]Strati 2017 — New Evidences on the Altered Gut Microbiota in Autism Spectrum DisordersFrancesco Strati, Duccio Cavalieri, Davide Albanese et al. · 2017Open reference 2 ↓}

Hypertension#

Malassezia abundance increases progressively from normotensive to pre-hypertensive to hypertensive subjects (significant between HTN and NT).^{[3]Gut mycobiome dysbiosis contributes to the development of hypertension and its response to immunoglobulin light chainsYeqing Zou, Anxing Ge, Brako Lydia et al. · 2022Open reference 3 ↓}

Positively associated with immunoglobulin light chain kappa in pre-HTN (r=0.510, P=0.044) and both kappa and lambda in HTN, suggesting immune activation by Malassezia antigens.

Fungal dysbiosis detected already at the pre-hypertension stage, suggesting mycobiome changes precede clinical hypertension.

Broader Cardiometabolic Disease#

Enriched in HTN+CKD comorbidity (18.71% of fungal community vs lower in controls).^{[4]Exploring the gut mycobiome: differential composition and clinical associations in hypertension, chronic kidney disease, and their comorbidityJuan Qiu, Longyou Zhao, Yiwen Cheng et al. · 2023Open reference 4 ↓} Increased in atherosclerotic CVD alongside Exophiala, Penicillium, and Wallemia.^{[5]Gut mycobiome in cardiometabolic disease progression: current evidence and future directionsXiaoyu Wei, Zixin Guo, Jingyang Wang et al. · 2025Open reference 5 ↓} Also enriched in obesity: M. restricta increased in obese individuals.

Immunomodulatory Properties#

Malassezia cell wall components (mannans, beta-glucans) activate Dectin-1, Dectin-2, and TLR2 on innate immune cells. Produces arachidonic acid metabolites via phospholipase activity that can modulate local inflammation. Immunoglobulin light chain dysregulation associated with Malassezia enrichment in hypertension suggests a novel immune-fungal-cardiovascular axis.

In IBD, Malassezia may activate CARD9-dependent immune pathways in genetically susceptible individuals.

Oral-Gut-Skin Axis#

Malassezia presence in three body niches (skin, oral cavity, gut) raises the possibility of a fungal oral-gut-skin axis. Skin Malassezia infections may seed gut colonization via ingestion; conversely, gut immune responses to Malassezia may influence skin disease.

This multi-niche colonization is relevant to systemic diseases like Cardiovascular Disease where both gut and skin microbiome alterations have been documented.

Key Metabolites#

Lipase products—oleic acid and other unsaturated fatty acids from sebum/lipid metabolism; inflammatory triggers. Indole derivatives—some Malassezia species produce tryptophan-derived metabolites that act as aryl hydrocarbon receptor (AHR) ligands, modulating skin and gut immune responses. Arachidonic acid metabolites—phospholipase-derived inflammatory mediators.